Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Fluconazole and CTP-543 in Healthy Subjects
NCT05478772Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deuruxolitinib in alopecia areata, sponsored by Concert Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Jul 2022; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05478772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478772.